Free Trial
NASDAQ:FBIO

Fortress Biotech (FBIO) Stock Price, News & Analysis

Fortress Biotech logo
$2.35 +0.06 (+2.62%)
Closing price 08/26/2025 04:00 PM Eastern
Extended Trading
$2.44 +0.09 (+3.83%)
As of 06:55 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Fortress Biotech Stock (NASDAQ:FBIO)

Key Stats

Today's Range
$2.28
$2.49
50-Day Range
$1.71
$2.35
52-Week Range
$1.33
$2.49
Volume
889,377 shs
Average Volume
297,595 shs
Market Capitalization
$69.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.50
Consensus Rating
Buy

Company Overview

Fortress Biotech Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
56th Percentile Overall Score

FBIO MarketRank™: 

Fortress Biotech scored higher than 56% of companies evaluated by MarketBeat, and ranked 450th out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Fortress Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Fortress Biotech has only been the subject of 1 research reports in the past 90 days.

  • Read more about Fortress Biotech's stock forecast and price target.
  • Earnings Growth

    Earnings for Fortress Biotech are expected to grow in the coming year, from ($3.28) to ($1.13) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Fortress Biotech is -2.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Fortress Biotech is -2.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Fortress Biotech has a P/B Ratio of 1.87. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Fortress Biotech's valuation and earnings.
  • Percentage of Shares Shorted

    14.10% of the float of Fortress Biotech has been sold short.
  • Short Interest Ratio / Days to Cover

    Fortress Biotech has a short interest ratio ("days to cover") of 14.7, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Fortress Biotech has recently decreased by 4.79%, indicating that investor sentiment is improving.
  • Dividend Yield

    Fortress Biotech does not currently pay a dividend.

  • Dividend Growth

    Fortress Biotech does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    14.10% of the float of Fortress Biotech has been sold short.
  • Short Interest Ratio / Days to Cover

    Fortress Biotech has a short interest ratio ("days to cover") of 14.7, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Fortress Biotech has recently decreased by 4.79%, indicating that investor sentiment is improving.
  • News Sentiment

    Fortress Biotech has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.98 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 18 news articles for Fortress Biotech this week, compared to 1 article on an average week.
  • Search Interest

    8 people have searched for FBIO on MarketBeat in the last 30 days. This is an increase of 167% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added Fortress Biotech to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Fortress Biotech insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    27.90% of the stock of Fortress Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    96.51% of the stock of Fortress Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Fortress Biotech's insider trading history.
Receive FBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fortress Biotech and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

FBIO Stock News Headlines

What is HC Wainwright's Forecast for FBIO Q3 Earnings?
The Coin That Could Define Trump’s Crypto Presidency
When Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top advisor on crypto and AI. That alone signaled a shift. But insiders close to D.C. aren’t just talking crypto policy—they’re quietly buying something most retail investors have missed. While the crowd chases Bitcoin to $150,000, Weiss Ratings expert Juan Villaverde believes a different coin—already backed by giants like Google, Visa, and PayPal—could soon become crypto’s “Third Giant.”tc pixel
Roth Capital Expects Increased Earnings for Fortress Biotech
See More Headlines

FBIO Stock Analysis - Frequently Asked Questions

Fortress Biotech's stock was trading at $2.03 at the beginning of 2025. Since then, FBIO stock has increased by 15.8% and is now trading at $2.35.

Fortress Biotech, Inc. (NASDAQ:FBIO) announced its quarterly earnings data on Thursday, August, 14th. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.31) by $0.15. The biopharmaceutical company had revenue of $16.41 million for the quarter, compared to analysts' expectations of $14.53 million. Fortress Biotech had a negative trailing twelve-month return on equity of 301.81% and a negative net margin of 24.84%.

Fortress Biotech shares reverse split on the morning of Tuesday, October 10th 2023.The 1-15 reverse split was announced on Monday, October 9th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 9th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Fortress Biotech's top institutional shareholders include Shikiar Asset Management Inc. (0.94%), Envestnet Asset Management Inc. (0.57%), 180 Wealth Advisors LLC (0.31%) and Atria Investments Inc (0.30%). Insiders that own company stock include Lindsay A Md Rosenwald, Dov Klein and David Jin.
View institutional ownership trends
.

Shares of FBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Fortress Biotech investors own include Plug Power (PLUG), FuelCell Energy (FCEL), Workhorse Group (WKHS), KALA BIO (KALA), Ovid Therapeutics (OVID), Lipocine (LPCN) and Comtech Telecommunications (CMTL).

Company Calendar

Last Earnings
8/14/2025
Today
8/26/2025
Next Earnings (Estimated)
11/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:FBIO
CIK
1429260
Employees
170
Year Founded
2006

Price Target and Rating

High Price Target
$17.00
Low Price Target
$16.00
Potential Upside/Downside
+602.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.05)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$46 million
Net Margins
-24.84%
Pretax Margin
-150.15%
Return on Equity
-301.81%
Return on Assets
-27.48%

Debt

Debt-to-Equity Ratio
1.34
Current Ratio
1.92
Quick Ratio
1.70

Sales & Book Value

Annual Sales
$57.67 million
Price / Sales
1.21
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.26 per share
Price / Book
1.87

Miscellaneous

Outstanding Shares
29,750,000
Free Float
21,453,000
Market Cap
$69.91 million
Optionable
Optionable
Beta
1.76

Social Links

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:FBIO) was last updated on 8/27/2025 by MarketBeat.com Staff
From Our Partners